Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as the Gold Standard Neoadjuvant Chemotherapy Regimen for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer Remains Controversial

J Clin Oncol. 2022 Sep 10;40(26):3093-3094. doi: 10.1200/JCO.22.00669. Epub 2022 Jun 15.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Cisplatin / adverse effects
  • Cystectomy
  • Doxorubicin / adverse effects
  • Humans
  • Methotrexate / adverse effects
  • Muscles
  • Neoadjuvant Therapy
  • Neoplasm Invasiveness
  • Urinary Bladder Neoplasms* / pathology
  • Vinblastine / adverse effects

Substances

  • Vinblastine
  • Doxorubicin
  • Cisplatin
  • Methotrexate